288 related articles for article (PubMed ID: 18798018)
1. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
Jessen C; Agerbaek M; Von Der Maase H
Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
[TBL] [Abstract][Full Text] [Related]
2. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
[TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy in advanced transitional cell carcinoma of the urinary tract. Phase II trial of a combination of doxorubicin and cisplatin].
Ribrag V; Ghnassia M; Théodore C; Ghosn M; Piot G; Beurton D; Cukier J; Droz JP
J Urol (Paris); 1990; 96(7):373-4. PubMed ID: 2290037
[TBL] [Abstract][Full Text] [Related]
5. Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience.
Yamamoto N; Tamura T; Fukuoka M; Saijo N
Int J Oncol; 1999 Oct; 15(4):737-41. PubMed ID: 10493956
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus.
Zhang X; Shen L; Li J; Li Y; Li J; Jin M
Am J Clin Oncol; 2008 Feb; 31(1):29-33. PubMed ID: 18376224
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
[TBL] [Abstract][Full Text] [Related]
8. [Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis].
Wang CT; Cao KJ; Li Y; Xie GF; Huang PY
Ai Zheng; 2007 Feb; 26(2):212-5. PubMed ID: 17298756
[TBL] [Abstract][Full Text] [Related]
9. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
De Santis M; Bachner M
Curr Opin Urol; 2007 Sep; 17(5):363-8. PubMed ID: 17762632
[TBL] [Abstract][Full Text] [Related]
10. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
Gholam D; Fizazi K; Terrier-Lacombe MJ; Jan P; Culine S; Theodore C
Cancer; 2003 Aug; 98(4):745-52. PubMed ID: 12910518
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-II combined intra-arterial chemotherapy for locally advanced bladder cancer: a case series study at a single institution.
Shimabukuro T; Nakamura K; Uchiyama K; Tei Y; Aoki A; Naito K
Hinyokika Kiyo; 2006 Feb; 52(2):99-105. PubMed ID: 16541762
[TBL] [Abstract][Full Text] [Related]
12. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.
Sengeløv L; Kamby C; Geertsen P; Andersen LJ; von der Maase H
Cancer Chemother Pharmacol; 2000; 46(5):357-64. PubMed ID: 11127939
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
[TBL] [Abstract][Full Text] [Related]
15. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
Yamada Y; Itoh Y; Aoki S; Nakamura K; Taki T; Naruse K; Tobiume M; Zennami K; Katsuda R; Kato Y; Watanabe M; Nishikawa G; Minami M; Nakahira M; Ukai S; Sawada M; Kitamura A; Honda N
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1079-83. PubMed ID: 19277660
[TBL] [Abstract][Full Text] [Related]
16. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy.
Kastritis E; Dimopoulos MA; Antoniou N; Deliveliotis C; Chrisofos M; Skolarikos A; Gika D; Bamias A
Anticancer Res; 2006; 26(5B):3865-9. PubMed ID: 17094415
[TBL] [Abstract][Full Text] [Related]
17. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.
Abe T; Shinohara N; Harabayashi T; Sazawa A; Maruyama S; Suzuki S; Nonomura K
Eur Urol; 2007 Oct; 52(4):1106-13. PubMed ID: 17367917
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
Schmidt H; Geertsen PF; Fode K; Rytter C; Bastholt L; von der Maase H
Melanoma Res; 2000 Feb; 10(1):66-77. PubMed ID: 10711642
[TBL] [Abstract][Full Text] [Related]
20. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]